The Department of Health and Human Services, through the National Institute on Aging (NIA), has issued a funding opportunity titled "Seamless Early-Stage Clinical Drug Development for Novel Therapeutic Agents for Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative seeks to streamline early-stage clinical trials by combining phase 1 with phase 1b/phase 2a trials for promising pharmacological interventions that focus on non-amyloid/non-tau mechanisms addressing cognitive or neuropsychiatric symptoms in individuals at various disease stages. The application must detail prespecified safety and tolerability milestones to progress through clinical phases. Key eligibility includes a range of organizations, including higher education institutions and nonprofits, with a project duration of up to five years. The initiative aims to accelerate the development of new treatments against Alzheimer’s, reflecting a critical need as the aging population rises, and the economic burden of AD/ADRD escalates. Eligible applicants are encouraged to enhance diversity in research, with an emphasis on robust data management and sharing practices. The proposal outlines a cooperative agreement format, emphasizing substantial federal involvement in managing and monitoring projects through defined guidelines and milestones. Overall, this funding opportunity highlights the federal government's commitment to advancing Alzheimer's research and therapeutic innovations.